Subsidy Information and Financing Scheme MSHLPemigatinib Tablet 4.5 mg, 9 mg, 13.5 mg Treatment of patients with locally advanced or metastatic cholangiocarcinoma with a FGFR2 fusion or... See all × MSHLPemigatinib Tablet 4.5 mg, 9 mg, 13.5 mg Treatment of patients with locally advanced or metastatic cholangiocarcinoma with a FGFR2 fusion or rearrangement that has progressed after at least one prior line of systemic therapy.
General Availability in Public Healthcare Institution Users are to consult the respective PHIs for actual inventory availability and supply restrictions/consideration Tablet 9 mg National Cancer Centre Tablet 13.5 mg National Cancer Centre
ORAL Select a brand starting with the letter: P PEMAZYRE TABLETS 13.5 MG [SIN17044P] PEMAZYRE TABLETS 4.5 MG [SIN17042P] PEMAZYRE TABLETS 9 MG [SIN17043P]